Financial StabilityBioxcel Therapeutics has successfully renegotiated its credit agreement, which helps address the company's cash concerns.
Regulatory ApprovalThere is a relatively high chance that the FDA could approve at-home use for schizophrenia/bipolar disorder patients, given the solidity of the data in the SERENITY Phase 3 program.
Revenue PotentialThe initiation of the Phase 3 SERENITY At-Home study for Igalmi is seen as a positive development, potentially driving increased revenue.